Dehydro aripiprazole
aripiprazole metabolite
What it isThe dehydro metabolite of aripiprazole, a D2 partial agonist with similar affinity and a longer half-life.
Why it mattersIt represents about 40% of total exposure, so aripiprazole’s effect is really the sum of two long-lived partial agonists.
What it changesIt is part of why aripiprazole takes two weeks to reach steady state and why akathisia can emerge late.
FDA-approved for
- schizophrenia/bipolar (metabolite of aripiprazole)
NO BOXED WARNINGS
Principal riskLittle in its own right; see the parent drug
Classes and tags
Clinical profile
Mechanism of action: Dehydro aripiprazole ballicule
